Search Tag: ESC Congress 2024
2024 30 Aug
New research presented at ESC Congress 2024 showed that discontinuing beta-blockers in patients with a history of myocardial infarction (MI) did not demonstrate cardiovascular safety compared to continuation and provided no improvement in patients' quality of life. Advancements in MI management and findings from observational studies have...Read more
2024 30 Aug
Late-breaking research presented at a Hot Line session at ESC Congress 2024 found no significant difference in major post-operative complications between patients who continued versus those who stopped renin-angiotensin system inhibitors (RASIs) before non-cardiac surgery. Many patients undergoing major surgery have a history of hypertension,...Read more
2024 30 Aug
The updated ESC Guidelines on managing elevated blood pressure and hypertension introduce a new "elevated BP" category, set more ambitious treatment targets, and, for the first time, recommend renal denervation for treating various forms of hypertension. Hypertension and elevated blood pressure are the most prevalent risk factors for heart...Read more
2024 30 Aug
Vutrisiran significantly reduced mortality, cardiovascular events, and markers of disease progression in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to late-breaking research presented today in a Hot Line session at ESC Congress 2024. ATTR is a progressive, fatal disease characterised by the accumulation...Read more
2024 30 Aug
The 2024 ESC Guidelines for the Management of Peripheral Arterial and Aortic Diseases (PAAD) approach these vascular conditions as interconnected components of the cardiovascular system, acknowledging that patients with aortic diseases often have a concurrent risk of peripheral vascular diseases and vice versa. Although primarily aimed at cardiologists,...Read more